<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227369</url>
  </required_header>
  <id_info>
    <org_study_id>111720</org_study_id>
    <nct_id>NCT01227369</nct_id>
  </id_info>
  <brief_title>Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate
      treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in
      Korean postmenopausal osteoporosis patients with bisphosphonate treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean of composite satisfaction score (CSS) of OPSAT-QTM</measure>
    <time_frame>0day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean of subscale satisfaction scores of OPSAT-QTM</measure>
    <time_frame>oday</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4376</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Bisphosphonates</arm_group_label>
    <description>Korean postmenopausal osteoporosis patients with bisphosphonate treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OPSAT-Q</intervention_name>
    <description>A linguistically validated Korean version of OPSAT-Q</description>
    <arm_group_label>Bisphosphonates</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        According to 2006 national health insurance data, a total of osteoporosis women (ICD-10
        code: M81) are about 244,190 in Korea According to recent market research data, 95% of
        osteoporosis women use bisphosphonate in Korea.

        With considering 95% market share of bisphosphonate in osteoporosis market, there are
        231,714 Korean osteoporosis women. Applying for 2% extracting fraction in this study, total
        size of study population are 4,634.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Who have been diagnosed with postmenopausal osteoporosis by physician Who have
             received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide
             answer of OPSAT-QTM questionnaire Who provide informed consent for study participation

        Exclusion Criteria:

          -  Do not understand the contents of the questionnaire
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bisphosphonates</keyword>
  <keyword>OPSAT-Q</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

